Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

n 2007 to be $1,400,000 per month and we believe our existing capital resources are adequate to fund our current plans for research and development activities well into 2009. Factors that will affect our anticipated monthly burn rate include, but are not limited to, the number of manufacturing runs required to supply our clinical trial program and the cost of each run, additional activities reducing our economic dependence on a single supplier, the number of clinical trials ultimately approved, the timing of patient enrollment in the approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of the NCI's R&D activity, and the level of pre-clinical activity undertaken.

In the event that we choose to seek additional capital, we will look to fund additional capital requirements primarily through the issue of additional equity. We recognize the challenges and uncertainty inherent in the capital markets and the potential difficulties we might face in raising additional capital. Market prices and market demand for securities in biotechnology companies are volatile and there are no assurances that we will have the ability to raise funds when required.

Capital Expenditures

We spent $586,124 on intellectual property during the nine month period ending September 30, 2007 compared to $552,319 during the nine month period ending September 30, 2006. The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base. As well, we have benefited from a stronger Canadian dollar as our patent costs are typically incurred in U.S. currency. In the third quarter of 2007, two U.S. patents were issued bringing our total patents issued to 23 in the U.S. and six in Canada.

Investing Activities

Under our Investment Policy, we are permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 ... based on the products of cells grown under ... entered into an international license agreement with Suneva ... proprietary multipotent cell conditioned media (CCM). ... existing license between Histogen and Suneva Medical, through ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research ... ALQA). Alliqua is an emerging biomedical company acquiring, ... the wound care market. , Free report download: ... was restructured with a seasoned management team and ... become a leading provider of wound care products. ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader ... as the new Director of Product Strategy. In this ... as well as iLab sub-teams to guide in the ... to ensure that iLab provides the maximum possible benefit ... user-friendly, and high-impact solution in the world. , ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ... to challenges related to patient safety, clinical outcomes, ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Based on the clinical success,of its facet replacement ... has expanded its executive management team and established,its ... Massachusetts,allows us to consolidate our operations in one ... gives us access to a wealth of,talent in ...
... Winners of 2008 R&D 100 Awards Now Online, ... the,finalists for the 8th Annual Innovator of the Year ... individuals who exemplify the,ideals of R&D in academia, industry, ... facilitated online with ten finalists,-- five scientists and five ...
... pleased to announce that Dr. Francis Stoessel, a leading ... will be the Keynote Speaker in the Process Safety ... ... Columbia, MD (PRWEB) October ...
Cached Biology Technology:Facet Solutions Establishes Corporate Headquarters and Expands Executive Team 22008 R&D Innovator of the Year & Scientist of the Year Finalists Announced 2
(Date:4/15/2014)... nanoparticle form could help reduce side effects by targeting ... scientists have developed nanoparticles that deliver one or two ... design particles that can carry any more than that ... devised a new way to build such nanoparticles, making ... drugs. In a paper published in the Journal ...
(Date:4/15/2014)... become clear that the genetic code is far ... the well-known building blocks adenine, cytosine, guanine, and ... Scientists now assume that the newly discovered nucleic ... information that extends and complements the genetic code. ... extend the standard alphabet," explained Professor Mark Helm ...
(Date:4/15/2014)... Rosemont, IL (April 15, 2014) New research ... Journal of the American College of Nutrition shows ... exercise or as part of a weight-loss or weight-maintenance ... body composition. , The meta-analysis included 14 randomized ... When researchers analyzed those weight loss studies that used ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3German Research Foundation approves new priority program in the life sciences 2New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3
... Terrace, Ill., March 8, 2010 Americans recognize things need ... Sam,s efforts to overhaul what is included in their food ... are individually responsible for making the right food choices to ... be successful, according to a new survey by FoodMinds. ...
... the fractious debate on the existence of God and ... the discussion. Taking a perspective rooted in evolutionary biology ... (Prometheus Books, $25) renowned anthropologist Lionel Tiger and pioneering ... is its purpose? How did it arise? What is ...
... problems have to be fed intravenously. There moreover, exist systems ... Mr Iaki Irastorza, paediatrician at the Cruces hospital in Bilbao, ... children were treated at the Great Ormond Street Children,s Hospital ... highly novel PhD thesis at the University of the Basque ...
Cached Biology News:Americans want Uncle Sam's help putting healthy foods on their dinner table 2Which came first: Religion or the brain? 2First time research on long-term consequences of intravenous nutrition on children's health 2First time research on long-term consequences of intravenous nutrition on children's health 3